LP
Lighthouse Pharma develops selective protease inhibitors targeting P. gingivalis-positive Alzheimer's disease and other chronic inflammatory disorders. Their precision medicine approach utilizes extensive clinical data to enhance treatment efficacy for conditions with significant unmet medical needs, including dementia and periodontal disease.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Lighthouse Pharma develops selective protease inhibitors targeting P. gingivalis-positive Alzheimer's disease and other chronic inflammatory disorders. Their precision medicine approach utilizes extensive clinical data to enhance treatment efficacy for conditions with significant unmet medical needs, including dementia and periodontal disease.